北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学深圳医院  > 检验科  > 期刊论文
学科主题: 临床医学
题名:
Vaginal Nystatin Versus Oral Fluconazole for the Treatment for Recurrent Vulvovaginal Candidiasis
作者: Fan, Shangrong1,2; Liu, Xiaoping3; Wu, Cong1; Xu, Lixuan1; Li, Jianling1
关键词: Recurrent vulvovaginal candidiasis ; Candida ; Antifungal susceptibility ; Nystatin ; Fluconazole
刊名: MYCOPATHOLOGIA
发表日期: 2015-02-01
DOI: 10.1007/s11046-014-9827-4
卷: 179, 期:1-2, 页:95-101
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Mycology
研究领域[WOS]: Mycology
关键词[WOS]: ANTIFUNGAL SUSCEPTIBILITIES ; SOUTHERN CHINA ; VAGINITIS ; THERAPY ; CANDIDOSIS ; GUIDELINES ; MANAGEMENT ; WOMEN
英文摘要:

Recurrent vulvovaginal candidiasis (RVVC) is a common condition that can physically and psychologically impact patients. We compared the efficacy and safety of vaginal nystatin suppositories for 14 days each month versus standard oral fluconazole regimens for the treatment for RVVC. Patients (n = 293) were enrolled in the study from April 2010 to September 2013. After the initial therapy, the mycological cure rates were 78.3 % (119/152) and 73.8 % (104/141) in the nystatin group and fluconazole group, respectively (95 % CI, 0.749-2.197, p > 0.05). The mycological cure rates at the end of maintenance therapy were 80.7 % (96/119) and 72.7 % (72/99) in the two groups, respectively (95 % CI, 0.954-3.293, p > 0.05).The mycological cure rates at the end without treatment for 6 months were 81.25 % (78/96) and 82.19 % (60/73) in the two groups, respectively (95 % CI, 0.427-2.066, p > 0.05). The mycological cure rates of RVVC caused by C. albicans were 84.0 % (89/106) and 81.8 % (99/121) in the two groups, respectively. The mycological cure rates of RVVC caused by C. glabrata were 64.3 % (27/42) and 12.5 % (2/16) in the two groups, respectively. The initial and 6-month maintenance therapy were successful in five of the nine patients in the nystatin group with RVVC caused by fluconazole-resistant Candida, whereas in the fluconazole group, initial therapy failed in all patients with RVVC caused by fluconazole-resistant Candida (n = 7). We conclude that both fluconazole and nystatin therapies are effective in treating RVVC. Nystatin may also be effective for the treatment for RVVC caused by C. glabrata or fluconazole-resistant Candida.

语种: 英语
所属项目编号: 201201001
项目资助者: Shenzhen Science and Technology
WOS记录号: WOS:000349528700011
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/50570
Appears in Collections:北京大学深圳医院_检验科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ Shenzhen Hosp, Dept Obstet & Gynaecol, Shenzhen 518036, Peoples R China
2.Shenzhen Key Lab Gynecol Diagnost Technol Res, Shenzhen 518036, Peoples R China
3.Peking Univ Shenzhen Hosp, Dept Lab Sci, Shenzhen 518036, Peoples R China

Recommended Citation:
Fan, Shangrong,Liu, Xiaoping,Wu, Cong,et al. Vaginal Nystatin Versus Oral Fluconazole for the Treatment for Recurrent Vulvovaginal Candidiasis[J]. MYCOPATHOLOGIA,2015,179(1-2):95-101.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Fan, Shangrong]'s Articles
[Liu, Xiaoping]'s Articles
[Wu, Cong]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Fan, Shangrong]‘s Articles
[Liu, Xiaoping]‘s Articles
[Wu, Cong]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace